Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 25:6:219-23.
doi: 10.2147/tcrm.s7245.

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Ege Can Serefoglu  1 , Zafer Tandogdu
Affiliations

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Ege Can Serefoglu et al. Ther Clin Risk Manag. .

Abstract

Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment with zoledronic acid.

Keywords: bisphosphonates; glucocorticoids; osteoporosis; zoledronic acid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage changes in BMD of lumbar spine in GIO patients treated with either daily risedronate or annual zoledronic acid (HORIZON). Abbreviations: BMD, bone mineral density; GIO, glucocorticoid-induced osteoporosis.
See this image and copyright information in PMC

References

    1. Kino T. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. Horm Metab Res. 2007;39(6):420–424. - PubMed
    1. Viegas LR, Hoijman E, Beato M, Pecci A. Mechanisms involved in tissue-specific apopotosis regulated by glucocorticoids. J Steroid Biochem Mol Biol. 2008;109(3–5):273–278. - PubMed
    1. Baxter JD, Rousseau GG. Glucocorticoid Hormone Action: an overview. Monogr Endocrinol. 1979;(12):1–24. - PubMed
    1. Cole TJ, Blendy JA, Monaghan AP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995;9(13):1608–1621. - PubMed
    1. Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 1998;95(16):9424–9429. - PMC - PubMed